Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 338

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 338
---
 initial business combination or the Company’s liquidation. For the year ended December 31, 2024, the Company incurred $ 200,000for the administrative support agreement, which is included in formation and operating costs on the statements of operations.

NOTE 6. PROMISSORY NOTE - LIMINATUS On October 4, 2023, the Company issued an unsecured promissory note in the aggregate principal amount up to $ 1,500,000to Liminatus. Pursuant to the Note, Liminatus agreed to loan to the Company an aggregate amount up to $ 1,500,000payable following the earlier of (i) closing of the Business Combination, as defined in the Business Combination Agreement dated November 30, 2022, or (ii) thirty ( 30) days following the termination of the Business Combination Agreement; provided, however, in the event the Company commences liquidation proceedings, this Note shall be cancelled and all amounts due, including all principal and accrued interest, shall be forgiven. Interest on the Note compounds annually and accrues on each unpaid Advance made under this Note at the rate of 5% per annum. On February 28, 2024, the Liminatus unsecured promissory note was amended and restated to increase the aggregate principal amount to up to $ 2,500,000, and add advances that occurred under the note. On August 2, 2024, the Liminatus unsecured promissory note was amended and restated to increase the aggregate principal amount to up to $ 3,500,000, and add advances that occurred under the note. On November 27, 2024, the Liminatus unsecured promissory note was amended and restated to increase the aggregate principal amount to up to $ 5,000,000, and add advances that occurred under the note. As of December 31, 2024 and December 31, 2023, the Company’s outstanding balance was $ 3,668,500, and including $ 818,500respectively. For the years ended December 31, 2024 and

<div align='center'>F-95</div>

December 31, 2023, the Company recorded interest expense of $ 119,843and $ 8,265, respectively, which is included within interest expense on the statements of operations and accounts payable and accrued expenses on the balance sheets. For the year ended December